STE — STERIS plc (Ireland)

Is STE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Neutral As of November 17, 2026

STERIS plc (Ireland) (STE) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $261.91. The rating moved from Overbought to Neutral on November 13, 2026.

AI analysis

STERIS combines durable recurring revenue from services and consumables with exposure to structural growth in surgical robotics, OR modernization and outsourced biopharma contamination-control services. The company’s diversified portfolio and aftermarket footprint support steady cash flow and margin resilience, while near-term growth is driven by instrument/consumable replacement cycles and expanding service contracts in life-sciences manufacturing. Headwinds include hospital capex sensitivity, competitive pricing pressure on consumables and potential regulatory/compliance costs. In a risk-off macro environment, order timing and execution are the main variables that will determine near-term performance; successful expansion in biopharma services and capture of robotics-related consumable spend are key upside catalysts.

Key factors

  • Leading market position in sterilization, infection prevention, surgical equipment and aftermarket services with durable recurring revenue streams
  • Exposure to surgical robotics and broader OR expansion that can drive instrument/consumable and service revenue
  • Growing biopharma services and contamination-control offerings benefiting from higher outsourcing in biologics manufacturing
  • Stable margin profile driven by a mix of products, consumables and high-margin services
  • Defensive demand for infection control products given ongoing regulatory and hospital emphasis on infection prevention
  • Diversified end markets (hospitals, life sciences, pharma) that reduce single-channel exposure

Risks

  • Hospital capital spending constraints or deferred elective procedures that reduce equipment orders and services
  • Competitive pressure on consumables and sterilization services from both large medtech peers and specialized entrants
  • Regulatory, quality or compliance actions (FDA, international regulators) that could disrupt shipments or increase remediation costs
  • Macro and rate environment that could pressure hospital budgets and slow M&A and capital investment activity
  • Supply-chain disruptions or commodity cost inflation compressing near-term margins
  • Execution risk on integration of acquisitions or scaling of biopharma services business lines

See today's live rating, score and targets

Members see the live hourly rating for STE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.